Director, Clinical Pharmacology
Remix Therapeutics
This listing was originally posted on Remix Therapeutics's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moRemix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs, 1) the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and 2) a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).
Position Summary:
The Director of Clinical Pharmacology will play a critical role in the design, execution, analysis, and interpretation of clinical pharmacology strategies across Remix Therapeutics' development programs. The initial focus of the role will be to lead the integrated clinical pharmacology strategy for REM-422, with primary responsibility for supporting late-stage development and potential regulatory submissions. The role will also provide clinical pharmacology leadership for emerging pipeline programs to support IND-enabling and early clinical development strategies.
The successful candidate will work in a highly cross-functional environment, partnering closely with Clinical Development, Regulatory Affairs, Clinical Operations, Biostatistics, DMPK, CMC and external collaborators to drive data-driven decision making and advance clinical development.
This is an opportunity to own the clinical pharmacology strategy for REM-422 as it advances toward a potential NDA, which would be Remix's first. You will shape dose selection, labeling, and regulatory strategy for an oral RNA-targeting therapy in ACC and AML/HR-MDS, and set the clinical pharmacology approach for the pipeline programs coming behind it.
Key Responsibilities:
Qualifications:
Salary Range:
$206,000 - $252,000 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.
Explore related positions you might be interested in
We'll notify you when matching roles are posted.
Interviewed at Remix Therapeutics?
Help others prepare — share your experience anonymously.
BIOTECHNOLOGY
Small molecule therapies designed to reprogram RNA processing
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo